CSL Inks $328M Deal with Memo Therapeutics for Next-Gen Antibody Tech

SCHLIEREN / ZURICH, Switzerland – February 09, 2026 – In a move signaling a potential paradigm shift in the treatment of immune disorders, global biotherapeutics leader CSL has entered into a strategic collaboration with Swiss biotech Memo Therapeutics AG (MTx). The deal, centered on MTx's innovative recombinant polyclonal IgG technology, includes an exclusive option-to-license agreement that could be worth up to CHF 265 million (USD 328 million) for the first product alone.

The partnership provides significant validation for MTx's proprietary DROPZYLLA® antibody discovery platform and marks a major investment by CSL into a future beyond traditional plasma-derived therapies. Under the terms, MTx will receive R&D funding and technology access fees to advance the development of its lab-engineered immunoglobulins. Should CSL exercise its option, the agreement unlocks a license fee, substantial development and sales milestones, and single-digit royalties.

“This collaboration with CSL represents further validation of our proprietary DROPZYLLA® technology platform and our shared ambition to advance innovative IgG solutions,” said Erik van den Berg, CEO of MTx, in a statement.

Dr. Michael Wilson, Senior Vice President of Global Research at CSL, commented on the synergy, stating, “This research collaboration combines CSL’s global leadership in immunoglobulins and expertise in recombinant proteins with Memo Therapeutics’ recombinant polyclonal technology to explore new treatment options for people with rare and serious diseases.”

A Strategic Pivot for an Industry Giant

The collaboration is particularly significant for CSL, a company whose legacy and market leadership are built upon plasma-derived medicines. For decades, CSL has been a dominant force in producing immunoglobulins (IgG) sourced from human blood plasma to treat a host of rare and serious conditions, including primary immunodeficiencies and autoimmune disorders. The company has invested billions in expanding its plasma collection and manufacturing infrastructure globally.

This multi-million-dollar bet on recombinant technology, however, underscores a strategic evolution. While plasma-derived therapies are effective, they rely on a complex and costly supply chain of human donors and can face challenges with batch-to-batch consistency. The industry is actively seeking alternatives that offer greater control, purity, and scalability.

By partnering with Memo Therapeutics, CSL gains access to a cutting-edge platform that could circumvent these traditional hurdles. This move aligns with CSL's stated R&D strategy, which balances its deep expertise in plasma with investments in recombinant technology, genetic medicine, and vaccines. It also reflects a broader industry trend where large pharmaceutical companies are increasingly looking to agile biotechs for breakthrough innovations, leveraging external partnerships to supplement their internal pipelines, especially as some, like CSL, have undergone recent R&D restructuring.

Industry analysts note that while recombinant polyclonal antibodies are unlikely to replace the entire standard immunoglobulin market overnight, they are perfectly positioned to create superior "hyperimmune" globulins. These are specialized therapies that require a defined mix of antibodies to target specific pathogens, an area where engineered precision offers a distinct advantage over the broad spectrum found in donated plasma.

The Science Behind the Deal: Recombinant IgG and DROPZYLLA®

At the heart of the agreement is a powerful technological leap: the shift from harvesting antibodies to engineering them. Recombinant polyclonal IgG antibodies are created in a laboratory setting, essentially mimicking the body's natural, diverse immune response without needing a single drop of blood plasma. This process promises therapies that are not only highly pure and consistent but can also be specifically tailored to fight particular diseases.

The key to unlocking this potential is Memo Therapeutics' proprietary DROPZYLLA® platform. Described as an antibody repertoire copying engine, DROPZYLLA® utilizes microfluidics to process millions of individual human B cells—the body's antibody factories. It can create "near complete" libraries of the antibodies a person has produced in response to a disease, achieving a level of coverage that the company claims is 100 times greater than conventional methods.

This allows scientists to find and clone ultra-rare but highly potent antibodies that would otherwise be missed. By preserving the natural pairing of antibody heavy and light chains, the platform ensures the resulting recombinant antibodies are functional and effective. This high-throughput system is what enables the development and, crucially, the manufacturing of a complex, controlled mixture of antibodies that constitutes a recombinant polyclonal IgG therapy.

While the production of any recombinant antibody faces challenges—such as achieving correct protein folding, stability, and the complex sugar patterns known as glycosylation that are critical for function—a successful platform like DROPZYLLA® represents a solution to a long-standing industry problem. It paves the way for a new class of medicines that could offer improved safety and efficacy for patients.

Redrawing the Competitive Landscape

The MTx-CSL partnership does not exist in a vacuum. It enters a dynamic and highly competitive therapeutic landscape. The market for monoclonal antibodies (mAbs)—single, highly specific antibodies—is a mature, multi-hundred-billion-dollar industry dominated by pharmaceutical giants treating cancer and autoimmune diseases. However, a single mAb cannot replicate the multifaceted attack of the body's natural polyclonal response.

This is where polyclonal antibodies, both plasma-derived and now recombinant, have their advantage. The collaboration between CSL and MTx firmly plants a flag in the nascent but rapidly growing recombinant polyclonal antibody space. While other companies are developing advanced antibody discovery platforms, this deal pairs MTx's leading-edge technology with CSL's global development, manufacturing, and commercialization power. This synergy creates a formidable force aimed at leading a new therapeutic category.

The move is seen as a direct challenge to the limitations of existing therapies and a signal to competitors that the future of immunoglobulin treatment is evolving. It positions both companies at the forefront of a shift toward more precise, powerful, and producible antibody medicines.

A New Horizon for Patients and MTx

Ultimately, the greatest potential of this collaboration lies in its promise for patients. For individuals living with congenital immunodeficiencies or complex autoimmune disorders, the development of recombinant polyclonal IgG could mean access to safer, more effective, and more reliable treatments. By moving away from plasma dependency, these next-generation therapies could alleviate supply chain vulnerabilities and offer a new standard of care.

For Memo Therapeutics, the deal is a transformative validation. It provides a substantial infusion of non-dilutive capital, allowing the Swiss company to aggressively pursue its development goals while retaining significant future upside through milestones and royalties. The endorsement from a global leader like CSL elevates the profile of not only its recombinant IgG program but its entire technological platform.

This partnership comes as MTx is already advancing its lead independent asset, potravitug, an antibody for treating BK polyomavirus (BKPyV) infection in kidney transplant recipients, toward a pivotal Phase III trial planned for 2026. The dual success of its internal pipeline and this major external collaboration solidifies Memo Therapeutics' position as a late-stage biotech company with a powerful, validated discovery engine capable of generating superior medicines for viral infections and beyond. The significant financial commitment from CSL is a clear indicator that the industry believes the era of engineered immunoglobulins has arrived.